Abbott Medical Optics (AMO) has received US Food and Drug Administration (FDA) approval to use its iFS Advanced Femtosecond Laser system to produce bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.
The system uses ophthalmic surgical lasers, indicated for use in patients undergoing surgery or treatment requiring the initial lamellar resection of the cornea. The laser is fifth generation IntraLase technology, enabling surgeons to make precise, bladeless arcuate incisions with greater precision, predictability and customisation compared to a manual technique, according to the company.
Following FDA clearance, Abbott’s iFS Femtosecond laser technology is available in the US. Jim Mazzo, AMO senior vice president, said the approval marks an advancement and expansion of the company’s Femtosecond system.
"This is an important step as we look to utilise Femtosecond laser technology as a potential standard of care during the cataract procedure," Mazzo added.
Previous study data supported the ability of iFS Femtosecond lasers to create arcuate incisions safely and effectively as prescribed by the physician and comply with applicable safety standards.
AMO is focused on providing the full range of refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages.
The company’s product portfolio includes monofocal and multifocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, excimer laser vision correction systems, treatment cards, disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears.